Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
Version 4.0 published: May 28, 2009 (v4.03: June14, 2010)."
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
Contents:; Biologics and the need for biosimilars -- Why do we need biosimilars? -- How is the quality of biosimilar medicines assured? -- Legal issues -- Switching, interchangeability and extrapolation -- Safety and pharmacovigilant -- Global issues -- Formulary considerations: pharmacy issues -- …
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency KEL Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency SUR Library | Available |
Contents:; 1. Mechanism of Chemotherapy in Cancer Treatment -- 2. Neutropenic Complications of Chemotherapy -- 3. Chemotherapy Induced Anemia -- 4. Cancer Treatment Related Thrombocytopenia -- 5. Oral Mucositis -- 6. Gastrointestinal Complications of Chemotherapy -- 7. Neurological Complications --…
Contents:; 1. Epidemiology, pathophysiology and classification -- 2. Clinical presentation -- 3. Diagnosis -- 4. Management -- 5. Treatment of associated conditions -- 6. Emerging research and treatment -- Useful resources.
Contents:; Marketing Yourself as a Clinical Nurse Leader -- Integration into CNL Practice : Preparing to Lead -- Leadership Within a Complex Environment -- Microsystem Assessment and the 5P?s -- Utilizing Evidence to Improve Practice -- Utilizing Data and Quality Improvement Principles -- Coordinat…
Contents:; 1: GENETIC MUTATIONS AND BIOMARKERS -- 2: UNDERSTANDING NEXT-GENERATION SEQUENCING -- 3: ELEMENTS OF COMPREHENSIVE GENOMIC PROFILES -- 4: ROLE IN PRECISION ONCOLOGY -- 5: PREDICTIVE AND PROGNOSTIC BIOMARKERS -- 6: OVERCOMING BARRIERS TO GENOTYPE-DIRECTED THERAPY